3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Neoplasms by Site
1
Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Breast Neoplasms
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Interventions
pembrolizumab
42
Specimen Handling
38
Magnetic Resonance Spectroscopy
30
Carboplatin
30
Cyclophosphamide
27
Biopsy
25
Nivolumab
23
Dexamethasone
22
fludarabine
21
Gemcitabine
19
Bevacizumab
15
Paclitaxel
14
Temozolomide
13
Pemetrexed
13
Docetaxel
13
Cisplatin
13
atezolizumab
12
Ipilimumab
12
Rituximab
11
venetoclax
10
Prednisone
10
Lenalidomide
9
Injections
9
Fulvestrant
9
lenvatinib
8
X-Rays
8
Vincristine
8
Trastuzumab
8
Oxaliplatin
8
Fluorouracil
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
RAD1901
×
30 days
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled